Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study Anne McLeer-Florin, PhD, Denis Moro-Sibilot,

Slides:

Advertisements

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Advertisements

Naomi Fujioka, MD, Christopher A. French, MD, Michael J

Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non- small Cell Lung Cancer? Cecilia Bozzetti, PhD, Marcello Tiseo, MD, Costanza.

Detection of TMPRSS2-ETS Fusions by a Multiprobe Fluorescence in Situ Hybridization Assay for the Early Diagnosis of Prostate Cancer Qi-Peng Sun, Liao-Yuan.

Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.

Detection of TMPRSS2-ETS Fusions by a Multiprobe Fluorescence in Situ Hybridization Assay for the Early Diagnosis of Prostate Cancer Qi-Peng Sun, Liao-Yuan.

New Methods for ALK Status Diagnosis in Non–Small-Cell Lung Cancer: An Improved ALK Immunohistochemical Assay and a New, Brightfield, Dual ALK IHC–In.

EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies Sandra Salvi, PhD, Serena Varesano, PhD, Simona.

Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.

ALK FISH and IHC: You Cannot Have One without the Other

A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer Shinjiro.

Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision.

FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.

Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm Heounjeong Go, MD, PhD, Dong-Wan Kim,

High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer Marcel Wiesweg, MD,

Fluorescence in Situ Hybridization Analysis of Immunoglobulin Heavy Chain Translocations in Plasma Cell Myeloma Using Intact Paraffin Sections and Simultaneous.

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib Trish Thorne-Nuzzo, BS, Crystal.

Anja C. Roden, MD, Patricia T. Greipp, DO, Darlene L. Knutson, Sara M

Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer Marta Salido, MSc, Lara Pijuan, MD, PhD, Luz Martínez-Avilés,

Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer Patrizia Viola, MD, Manisha Maurya,

MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases Jennifer M. Boland, MD, Jin.

Bright-Field Dual-Color Chromogenic In Situ Hybridization for Diagnosing Echinoderm Microtubule-Associated Protein-Like 4-Anaplastic Lymphoma Kinase-Positive.

Interpretation of Anti-ALK Immunohistochemistry Results

Comprehensive Hybrid Capture–Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative.

ALK and NRG1 Fusions Coexist in a Patient with Signet Ring Cell Lung Adenocarcinoma Lucia Anna Muscarella, PhD, Domenico Trombetta, PhD, Federico Pio.

A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib Akihiro Tamiya,

Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas Lynette M. Sholl, MD, Stanislawa Weremowicz,

ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung Anna Caliò, MD, Alessia Nottegar, MD, Eliana Gilioli, MD, Emilio Bria, MD, Sara.

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib Trish Thorne-Nuzzo, BS, Crystal.

Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment

Detection of Human Polyomavirus 7 in Human Thymic Epithelial Tumors

Searching for ROS1 Rearrangements in Lung Cancer by Fluorescent In Situ Hybridization: The Importance of Probe Design Arnaud Uguen, MD, Pascale Marcorelles,

A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK

Assessment of ALK Status by FISH on 1000 Spanish Non-Small Cell Lung Cancer Patients Joana Vidal, MD, Sergi Clavé, MSc, Silvia de Muga, PhD, Iria González,

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

MET Gene Status in Malignant Mesothelioma Using Fluorescent In Situ Hybridization Serena Varesano, PhD, Sandra Salvi, PhD, Simona Boccardo, PhD, Jean.

Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non–Small-Cell Lung Cancers Reveal Major Discordances Florian Cabillic, PharMD, PhD,

Role of Chromosome 3q Amplification in Lung Cancer

NUT Midline Carcinoma: An Aggressive Intrathoracic Neoplasm

ALK Testing in Lung Adenocarcinoma: Technical Aspects to Improve FISH Evaluation in Daily Practice Vittoria Martin, PhD, Barbara Bernasconi, PhD, Elisabetta.

A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas William.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

The Prognostic Value of Chromosome 7 Polysomy in Non-small Cell Lung Cancer Patients Treated with Gefitinib Lela E. Buckingham, PhD, John S. Coon, MD,

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon.

Erratum Journal of Thoracic Oncology

NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors

Arnaud Uguen, MD, PhD Journal of Thoracic Oncology

High MET Receptor Expression But Not Gene Amplification in ALK 2p23 Rearrangement Positive Non–Small-Cell Lung Cancer Yan Feng, MD, Eugen C. Minca, MD,

A Novel Mechanism of EML4-ALK Rearrangement Mediated by Chromothripsis in a Patient-Derived Cell Line Tatsushi Kodama, MS, Noriko Motoi, MD, PhD, Hironori.

Loss of p16INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas Scott W. Aesif, MD,

Amplification of MET in a Patient with Malignant Pleural Mesothelioma

Detection of ALK-Positive Non–Small-Cell Lung Cancers on Cytological Specimens: High Accuracy of Immunocytochemistry with the 5A4 Clone Spasenija Savic,

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for.

Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable.

Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib Sanjay Popat, MRCP, PhD, Alexandra Vieira de.

Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non–Small-Cell Lung Cancer Shengxiang Ren, MD, PhD, Fred.

A Novel Fusion of TPR and ALK in Lung Adenocarcinoma

Atypical Primary Epithelioid Hemangioendothelioma of the Heart

C-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas Koji Tsuta, MD, PhD, Yoshiki Kozu, MD, PhD, Takahiro.

Toni-Maree Rogers, BMLS, Prudence A

Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent

BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib Ling Shan, PhD, Peidi Jiang, MD, Feng Xu,

Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas Jun Fan, MD Journal of Thoracic.

Clinical Implications of Variant ALK FISH Rearrangement Patterns

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC- Positive and FISH-Negative ALK Jong-Mu Sun, MD, PhD, Yoon-La Choi,

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer Benjamin Solomon, MBBS, PhD, Marileila.

Presentation transcript:

Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study Anne McLeer-Florin, PhD, Denis Moro-Sibilot, MD, Adrien Melis, MD, Dimitri Salameire, MD, Christine Lefebvre, MD, PhD, Françoise Ceccaldi, Florence de Fraipont, PharmD, PhD, Elisabeth Brambilla, MD, PhD, Sylvie Lantuejoul, MD, PhD Journal of Thoracic Oncology Volume 7, Issue 2, Pages 348-354 (February 2012) DOI: 10.1097/JTO.0b013e3182381535 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Concordance between ALK immunohistochemical staining and fluorescence in situ hybridization signals. A, C, E, G, and I: ALK immunostainings using 5A4mAb (Immunoperoxidase, original magnification ×200). A and C, intense and cytoplasmic stainings (score 3+) with some membranar reinforcements, Panels E and G: no staining (score 0), and I: faint cytoplasmic staining (score 1+). B, D, F, H, and J show tumor nuclei hybridized with a dual-color ALK break-apart FISH probe (Vysis LSI ALK Dual Color, Break Apart Rearrangement Probe, Abbott Molecular). Nonrearranged ALK (F and H) shows fusion (orange signals) or very close apposition of the probes adjacent to the 3′ (red fluorophore) and the 5′ (green fluorophore) ends of the gene. Rearranged ALK (B, D, and J) is indicated by split 3′ (red) and 5′ (green) signals (B and J) or single red (3′) signals (D). J: background autofluorescence due to inappropriate fixation can be observed. (A, B); same patient, as well as (C, D), (E, F), (G, H), and (I, J). Journal of Thoracic Oncology 2012 7, 348-354DOI: (10.1097/JTO.0b013e3182381535) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions